Skip to content

Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis

Hämeenlinna Metabolic Syndrome Research Program (HMS): Surrogate Indicators for Atherosclerosis in Men With Metabolic Syndrome, Coronary Heart Disease and Controls

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01119404
Acronym
HMS-02
Enrollment
300
Registered
2010-05-07
Start date
2003-06-30
Completion date
2014-12-31
Last updated
2010-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease, Metabolic Syndrome

Keywords

Metabolic Syndrome, Coronary Heart Disease, Erectile Dysfunction, Arterial Elasticity, Oxidized Low Density Lipoprotein, Cardiovascular Diseases, Risk Assessment, Endothelial Dysfunction, Diabetes Mellitus, Surrogate Markers, Risk Factors

Brief summary

Mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. As a part of Hämeenlinna Metabolic Syndrome Research Program (HMS) surrogate indicators for atherosclerosis are studied in 120 men with metabolic syndrome, 120 men with coronary heart disease and 80 physically active controls and in different settings.

Detailed description

Accumulation of oxidized low-density lipoproteins (LDL) in the intimae of arteries together with risk factors known to enhance atherosclerosis, damage the endothelium of the arterial wall. Dysfunction of the endothelium leads into loss of elasticity of the artery. Surrogate indicators of atherosclerosis might be seen already in the early phase of otherwise subclinical arterial disease. In this study, we investigate calculated risk of the subjects (SCORE, FINRISK, Framingham score), platelet function and surrogate indicators for atherosclerosis like erectile dysfunction, plasma levels of oxidized LDL, arterial elasticity and biochemical markers for endothelial damage and dysfunction in different settings (case-only and case-control).

Interventions

None listed

Sponsors

Linnan Klinikka Oy
CollaboratorOTHER
Mehiläinen Hämeenlinna, Finland
CollaboratorUNKNOWN
Finnish Red Cross Blood Service
CollaboratorOTHER
Kanta-Häme Central Hospital
Lead SponsorOTHER_GOV

Study design

Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
MALE
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Group 1: Metabolic syndrome * 120 Finnish men with metabolic syndrome (MetS) defined according to National Cholesterol Education Program (NCEP) Adult Treatment Panel III * MetS diagnosed in routine health examination and laboratory tests * Age: 30 to 65 years Group 2: Coronary heart disease (CHD) * 120 Finnish men with angiographically proven CHD * Age: 30 to 65 years Group 3: Control * 80 Finnish men * Exercising physically more than three times a week and more than 30 minutes per exercise on regular basis * Never been studied or treated because of cardiovascular disease * Age: 30 to 65 years

Countries

Finland

Contacts

Primary ContactAri K Palomäki, MD PhD
ari.palomaki@khshp.fi+35836294540
Backup ContactKalevi Oksanen, MD PhD
kalevi.oksanen@khshp.fi+35836292369

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026